Designing Patient Hubs Purpose-Built for Cell and Gene Therapies
This Pharmaceutical Commerce article explores how purpose‑built patient hubs can streamline access, reduce barriers and better support the complex needs of cell and gene therapy patients. It was co‑authored by Ela Lourido, vice president and general manager of Biologics by McKesson, and Joe DePinto, head of cell, gene and advanced therapies for InspiroGene by McKesson.
How Proactive Specialty Pharmacy Care Helps Prevent Medication Waste
Read about how Biologics by McKesson uses proactive pharmacy care and personalized support to help patients stay on therapies, reduce costs and improve outcomes.
The Future of Oncology is Personal, and It’s Already Here
Learn how McKesson connects biopharma, providers and patients to deliver precision oncology at scale through integrated logistics, specialty pharmacy and high‑touch support.
AUGTYRO™ (Repotrectinib), FDA Approved for Treatment of AdvancedROS1-Positive & NTRK-Positive NSCLC, Available at Biologics by McKessonSpecialty Pharmacy in Limited Distribution Network
Cary, N.C., July 1, 2025 – Effective July 1st, Bristol Myers Squibb Co. has reduced its specialty pharmacy network for […]
IBTROZI™ (Taletrectinib), FDA-Approved Treatment, Available at Biologics by McKesson
Cary, N.C. , June 11, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
EMRELIS™ (telisotuzumab vedotin-tllv), FDA Approved for Treatment of Adult Patients with Previously Treated Non-Small Cell Lung Cancer, Available Exclusively at Biologics by McKesson
Cary, N.C. , May 20, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets,) FDA Approved for the Treatment of Adult Patients with KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer who have Received Prior Systemic Therapy, Available at Biologics by McKesson
Cary, N.C. , May 9, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
VANRAFIA (atrasentan), FDA Approved for Adults with Immunoglobulin A Nephropathy, Available at Biologics by McKesson
CARY, N.C., April 3, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected […]
GOMEKLI FDA Approved for Treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), Available at Biologics by McKesson
CARY, N.C., FEBRUARY 18, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]
Romvimza (vimseltinib), FDA Approved for Treatment of Tenosynovial Giant Cell Tumor (TGCT), Available at Biologics by McKesson
CARY, N.C., February 17, 2025—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been […]